Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026.
Share this article
Corporate
Score 72
Bullish
Why Allogene Therapeutics (ALLO) Says Its Lead Cancer Program Is Still on Track in 2026
Mar 29, 2026 20:46 UTC
ALLO, XLV, IHI
Medium term
Related Articles
Score 85
Bullish
Palantir Technologies Just Banked a Blockbuster Week. 3 Important Developments Every Shareholder Should Know.
Mar 29, 22:22
Score 85
Bullish
Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI
Mar 29, 20:54
Score 65
Bullish
How Datavault AI (DVLT) Reached Its First Profitable Quarter and Set a 2026 Growth Target
Mar 29, 20:53
Score 65
Bullish
Why Vertical Aerospace (EVTL) Is Expanding Its Valo Supplier Network Ahead of Certification
Mar 29, 20:52
Stay Ahead of the Markets
Join thousands of traders using AI-powered market intelligence. Get personalized insights, real-time alerts, and advanced analysis tools.